Allarity Therapeutics A/S, formerly known as ONCOLOGY VENTURE A/S, is a Danmark-based company engaged in the development of anticancer medicines. The Company s current priority program focus is on the advancement of three precision medicine treatments: 2X-121, Dovitinib and Ixempra targeting the market for the treatment of ovarian cancer, breast cancer, and renal cell carcinoma.